Shares of Cal-Maine Foods tumbled 9.3% to $80.10 in after-hours trading on July 17, extending a volatile stretch as investors brace for the company's next earnings report against a backdrop of repeated quarterly disappointments. Cal-Maine Slides 9% Days Before Earnings — Is the Egg Giant's Commodity Hangover a Buying Opportunity or a Warning Sign?
Shares of Cal-Maine Foods, the nation's largest egg producer, dropped 9.3% to $80.10 after hours on July 17, as investors de-risk ahead of next week's Q4 fiscal 2026 report. The company will release fourth-quarter and full fiscal year 2026 results on July 22. With egg prices cratering from last year's bird-flu-driven highs, the sell-off reflects growing unease over how badly profits have fallen — and whether management's diversification push can fill the gap.
• Plunging Egg Prices Are Crushing the Bottom Line. In the most recent quarter (Q3 fiscal 2026), net sales fell 53% to $667 million, gross profit collapsed 83.3% to $119.3 million, and diluted earnings per share dropped 89.8% to $1.06.
Cal-Maine now has roughly 9 million more laying hens than a year ago thanks to a milder avian flu season, pushing the average retail egg price down to about $2.50 per dozen. For a company whose revenue historically tracks spot egg prices, that arithmetic is brutal.
• Wall Street Expects Near-Zero Earnings Next Week. Analysts project just $0.08 per share in Q4 earnings on revenue of roughly $564 million — a fraction of the prior year's windfall. Benchmark's analyst noted that Q3's 90% year-over-year EPS drop "will occur again in Q4," and trimmed estimates further. The bar is low, but any miss could trigger another sharp leg down in a stock already 36% below its 52-week high of $126.40.
• Prepared Foods and Specialty Eggs Are the Bright Spot — But Still Small. Specialty eggs and prepared foods now account for 52.9% of net sales, with prepared foods surging 441% to $63.6 million. Management is investing $36 million to expand prepared-foods capacity by over 30%. But the core business remains "tied to commodity pricing," and these higher-margin products aren't yet large enough to offset a conventional-egg downturn of this magnitude.
• Legal Settlement Removes One Overhang, but Valuation Stays Uncertain. Cal-Maine recently reached a settlement with the DOJ and 17 state attorneys general over antitrust claims.
Analysts average a "Hold" rating with a 12-month target of $86.75 — barely 8% upside from the prior close. At a P/E of roughly 5.8x trailing earnings, the stock looks cheap, but that multiple reflects an earnings peak investors know won't repeat. The real question on July 22: Can management convince the market the trough is here, and that growth is on the other side?